Leukemoid Reaction to Parenteral Iron-Dextran Complex

Publisher Website
Google Scholar
Abstract
AN IBON-DEXTBAN COMPLEX (Imferon) used for parenteral treatment of iron deficiency anemia was recently rereleased for general use ' after a 2-year withdrawal from the market, which was occasioned by some reports of sarcoma production in experimental animals. Originally, the drug received considerable praise for its efficacy. Although present opinions vary, this iron-dextran complex was adjudged of sufficient merit to prompt its return to use in the U.S. However, continued caution in its use is advised and it is timely to consider its side effects. I present here a case report prepared at about the time of its removal from the American market and now especially relevant. In reporting a case of toxic reaction to intramuscular iron-dextran, manifest by arthralgia, Shafer and Marlow review the literature reported on toxic manifestations and conclude that these are infrequent. Skin rashes, local cellulitis, anaphylactoid reactions, and febrile reactions have been noted. In 1961, Ben-Ishay,

This publication has 0 references indexed in Scilit: